Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 13/20 | 0.49 |
| ▸ | ITGAV | P06756 | 12/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7075297 | 0.87 | ITGB3 (0.57) | ITGB3ITGAVMAPTKDM4EITGA2B | |
| SCHEMBL7401262 | 0.86 | ITGB3 (0.42) | ITGB3ITGAVMAPTKDM4EJAK2 | |
| SCHEMBL7917615 | 0.85 | ITGB3 (0.41) | ITGB3ITGAVMAPTKDM4EJAK2 | |
| SCHEMBL8525635 | 0.82 | JAK2 (0.46) | ITGB3ITGAVMAPTKDM4EJAK2 | |
| SCHEMBL7399767 | 0.81 | ALDH1A1 (0.40) | ITGB3ITGAVMAPT | |
| SCHEMBL4024909 | 0.80 | ITGB3 (0.57) | ITGB3ITGAVITGA2B | |
| SCHEMBL5155928 | 0.80 | ITGB3 (0.57) | ITGB3ITGAVITGA2B | |
| SCHEMBL4023860 | 0.80 | ITGB3 (0.57) | ITGB3ITGAVITGA2B | |
| SCHEMBL7437328 | 0.78 | ITGB3 (0.48) | ITGB3ITGAVMAPTKDM4EITGA2B | |
| SCHEMBL7437322 | 0.78 | ITGB3 (0.48) | ITGB3ITGAVMAPTKDM4EITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0946180-A4 | METHOD FOR STIMULATING BONE FORMATION | SMITHKLINE BEECHAM CORP (US) | 2003-07-23 | — | — | EP | disclosed |
| EP-0767792-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2002-11-20 | — | — | EP | disclosed |
| US-20020032187-A1 | Method for stimulating bone formation | SMITHKLINE BEECHAM CORPORATION | 2002-03-14 | — | — | US | disclosed |
| US-20020028812-A1 | Phenylalanine derivatives | CELLTECH CHIROSCIENCE LIMITED (GB) | 2002-03-07 | — | — | US | disclosed |
| US-5977101-A | Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity | SMITHKLINE BEECHAM CORPORATION (US) | 1999-11-02 | — | — | US | disclosed |
| EP-0946180-A1 | METHOD FOR STIMULATING BONE FORMATION | SMITHKLINE BEECHAM CORPORATION (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998015278-A1 | METHOD FOR STIMULATING BONE FORMATION | SMITHKLINE BEECHAM CORPORATION (US) | 1998-04-16 | — | — | WO | disclosed |
| EP-0767792-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-04-16 | — | — | EP | disclosed |
| WO-1996000730-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028812-A1 | Phenylalanine derivatives | PAH, FPR1, VCAM1 | ITGB3 18/4885ITGAV 53/4885MAPT 2071/4885 |
| US-20020032187-A1 | Method for stimulating bone formation | BMP2, BMP4, SOST | ITGB3 11/4885ITGAV 18/4885MAPT 4871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.